Pancreatic Cancer Research

ResearcherNanjing University of Chinese MedicineActive in the last 2 years

Ying Lv

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2058-7534; OpenAlex author ID A5101944199. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
26
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 7

  1. ALDH1A3 promotes the lung metastatic organotropism of pancreatic ductal adenocarcinoma through semaphorin signaling. Co-author DOI 10.1016/j.isci.2026.115950↗
  2. Epigenetic suppression of Nrf2-Slc40a1 axis induces ferroptosis and enhances immunotherapy in pancreatic cancer. Co-author DOI 10.1136/jitc-2025-013269↗
  3. Mitochondrial-targeted photodynamic therapy combined with TGF-β inhibition potentiates anti-PD-1 therapy in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12951-025-03795-z↗
  4. Analysis of T-cell receptor repertoire in peripheral blood of patients with pancreatic cancer and other pancreatic diseases. Last author DOI 10.1111/jcmm.16358↗
  5. Endoscopic Ultrasound-Guided Acquisition of Portal Venous Circulating Tumor Cells as a Potential Diagnostic and Prognostic Tool for Pancreatic Cancer. Last author DOI 10.2147/cmar.s330473↗
  6. ALDH1A3 Accelerates Pancreatic Cancer Metastasis by Promoting Glucose Metabolism. Co-author DOI 10.3389/fonc.2020.00915↗
  7. The Effects of HSP27 on Gemcitabine-Resistant Pancreatic Cancer Cell Line Through Snail. Co-author DOI 10.1097/mpa.0000000000000418↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaoping Zou · 5 shared papers, 2015–2026 · strength 0.62
  2. Shu Zhang · 4 shared papers, 2020–2025 · strength 0.60
  3. Shijin Xu · 2 shared papers, 2025 · strength 0.40
  4. Yixuan Zhang · 2 shared papers, 2025 · strength 0.40
  5. Xuetian Qian · 2 shared papers, 2020–2026 · strength 0.34
  6. Hongzhen Li · 2 shared papers, 2020–2026 · strength 0.34
  7. Shuang Nie · 2 shared papers, 2020–2026 · strength 0.34
  8. Lei Wang · 3 shared papers, 2020–2021 · strength 0.32
  9. Shanshan Shen · 3 shared papers, 2015–2021 · strength 0.27
  10. Shanshan Shen · 1 shared paper, 2026 · strength 0.24
  11. Yixuan Zhang · 2 shared papers, 2021 · strength 0.22
  12. Jiajun Zhang · 1 shared paper, 2025 · strength 0.21
  13. Ziwei Zhang · 1 shared paper, 2025 · strength 0.21
  14. Li Lin · 1 shared paper, 2025 · strength 0.21
  15. Lei Wang · 1 shared paper, 2025 · strength 0.19
  16. Jiatong Tang · 1 shared paper, 2025 · strength 0.19
  17. Xiaoping Zou · 1 shared paper, 2025 · strength 0.19
  18. Qi Li · 1 shared paper, 2025 · strength 0.19
  19. Jing Zhao · 1 shared paper, 2021 · strength 0.12
  20. Siqi Zhou · 1 shared paper, 2021 · strength 0.12
  21. Jie Yang · 1 shared paper, 2021 · strength 0.10
  22. Hui Wang · 1 shared paper, 2021 · strength 0.10
  23. Helmut Frieß · 1 shared paper, 2020 · strength 0.09
  24. Bin Zhang · 1 shared paper, 2020 · strength 0.09
  25. Bo Kong · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.